ENDRA Life Sciences Inc. (NDRA) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $5.30, NDRA has negative trailing earnings (P/E not meaningful) and an ROE of -310.93%. Market capitalisation stands at $7M.
Balance sheet quality for NDRA: current ratio of 1.3, net cash position of $270013. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $5.30 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.11 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -310.93% |
| Return on Invested Capital | -178.30% |
| Return on Assets | -182.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 7.10 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -43.65 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NDRA | ENDRA Life Sciences Inc. | $7M | 1.11 | -310.9% | |
| 0R0H.L | Thermo Fisher Scientific Inc. | $241.2B | 35.21 | 4.62 | 13.4% |
| TMO | Thermo Fisher Scientific Inc. | $241.0B | 36.16 | 4.74 | 13.4% |
| 0R2B.L | Danaher Corporation | $148.7B | 47.40 | 3.26 | 6.9% |
| DHR | Danaher Corporation | $146.6B | 36.91 | 2.80 | 7.7% |
| NTRA | Natera, Inc. | $49.5B | 27.40 | -11.7% | |
| 0HAV.L | Agilent Technologies, Inc. | $49.3B | 30.43 | 5.93 | 20.5% |
| 0JDM.L | IQVIA Holdings Inc. | $46.0B |
Price Performance
| 1 month | +17.52% |
| 3 months | +11.34% |
| Year-to-date | +17.00% |
| 1 year | +12.53% |
| 3 years | -99.75% |
| 5 years | -99.99% |
52-Week Range
| 52-week High | $9.85 |
| 52-week Low | $2.96 |
| Avg Volume (90d) | 36K |
Related companies: BBLG · BGMS · BNBX · DHAI · GCTK · HSCS · ISPC
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NDRA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks